Compare DexCom, Inc. (DXCM) vs Wynn Resorts, Limited (WYNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Wynn Resorts, Limited — how do they compare? DexCom, Inc. trades at $77.79 (market cap $28.06B), while Wynn Resorts, Limited trades at $98.05 (market cap $10.07B). The key difference: DexCom, Inc. is far larger — about 2.8× Wynn Resorts, Limited's market cap, and Wynn Resorts, Limited pays a 1.03% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | WYNN | |
|---|---|---|
Market Cap | $28.06B | $10.07B |
Sector | Health | Consumer Cyclical |
52-Week High | $89.53 | $133.34 |
52-Week Low | $54.84 | $94.78 |
Enterprise Value | $27.03B | $20.44B |
Dividend Yield | — | 1.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
Wynn Resorts (WYNN) trades at $98.57, up 2.78% today but down 13.4% year-to-date, reflecting mixed performance amid earnings volatility. The stock shows a bearish technical signal with resistance near $110, while fundamentals reveal revenue growth to $7.14B in 2025 but declining net margins to 4.58%. Recent Q1 2026 earnings met expectations at $1.25 EPS, though prior quarters missed estimates. Analyst sentiment remains strongly bullish with a $135 consensus target, but high debt and Macau competition pose risks.
The outlook for Wynn is cautiously optimistic, driven by luxury market recovery and analyst confidence, yet tempered by margin pressure and significant leverage. Investment opportunity lies in potential upside to price targets if execution improves, but risks include geopolitical impacts on international operations and sustained earnings misses. The stock's current valuation at 27.81 P/E requires careful monitoring of quarterly performance against expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Wynn Resorts, Limited
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.
Read more on WYNN →
